This reinforces our hypothesis that in DLBCL patients, an EBV-specific immune response is mounted locally and that inhibition of this immune response by, for example PD-1+ cells, may negatively affect outcome. This evidence concerns the gene PDCD1 and diffuse large B-cell lymphoma.